triple negative breast cancer foundation

Release time ：Nov-17,2024

The Triple Negative Breast Cancer Foundation is dedicated to the research, education, and support for triple negative breast cancer. This subtype of breast cancer is characterized by the absence of three specific receptors on cancer cell surfaces: estrogen receptors, progesterone receptors, and HER2, which limits treatment options.

Typically, the therapeutic approaches for triple negative breast cancer encompass surgery, radiation therapy, and chemotherapy. Given the insensitivity of this cancer to hormonal and targeted therapies, chemotherapy often serves as the primary systemic treatment. Surgical options, such as lumpectomy and mastectomy, are usually the first line of treatment, with the choice influenced by the tumor's location, size, and the patient's health status and personal preferences. Radiation therapy is generally administered postoperatively to minimize the risk of local recurrence. Chemotherapy may be applied preoperatively (neoadjuvant) to shrink the tumor and facilitate surgical removal or postoperatively (adjuvant) to eliminate any residual cancer cells.

For individuals diagnosed with triple negative breast cancer, it is imperative to seek timely medical care and professional treatment. Under a physician's guidance, patients should develop a personalized treatment plan and adhere to the prescribed treatment regimen. Additionally, maintaining healthy lifestyle practices, including a balanced diet, regular exercise, and routine health check-ups, can significantly enhance treatment efficacy and overall quality of life.